Proton pump inhibitors – do we know them well and are they really that safe? – part 3

6. Huijgen NA, de Ridder MAJ, Verhamme KM et al. Are proton-pump inhibitors harmful for the semen quality of men in couples who are planning pregnancy? Fertil Steril 2016; 106(7): 1666–1672. doi: 10.1016/ j.fertnstert. 2016.09.010.

18. Stangier J, Stähle H, Rathgen K et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47(1): 47–59. doi: 10.2165/ 00003088-200 847010-00005.

37. Makunts T, Cohen IV, Awdishu L et al. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities and nephrolithiasis. Sci Rep 2019; 9(1): 2282. 10.1038/ s41598-019-39335-7.

38. Makunts T, Alpatty S, Lee KC et al. Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory. Sci Rep 2019; 9(1): 17280. doi: 10.1038/ s41598-019-53622-3.

39. de la Coba Ortiz C, Arias FA, Mart C. Proton-pump inhibitors adverse efects: a review of the evidence and position statement by the Sociedad Espanola de Patologıa Digestiva. Rev Esp Enferm Dig 2016; 108(4): 207–224. doi: 10.17235/ reed.2016.4232/ 2016.

40. Joo MK, Park JJ, Chun HJ. Proton pump inhibitor: The dual role in gastric cancer. World J Gastroenterol 2019; 25(17): 2058–2070. doi: 10.3748/ wjg.v25.i17.2058.

41. Suissa S, Suissa A. Proton-pump inhibitors and increased gastric cancer risk: time-related biases. Gut 2018; 67(12): 2228–2229. doi: 10.1136/ gutjnl-2017-315729.

42. Abbas MK, Zaidi AZ, Robert CA et al. The safety of long-term daily usage of a proton pump inhibitor: A literature review 2019. Cureus 11(9): e5563. doi: 10.7759/ cureus.5563.

43. Poly TN, Islam MM, Yang HC et al. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int 2019; 30(1): 103–114. doi: 10.1007/ s00198-018-4788-y.

44. Targownik LE, Lix LM, Metge CJ et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008; 179(4): 319–326. doi: 10.1503/ cmaj.071330.

45. Thong BK, Ima-Nirwana S, Chin KY. Proton pump inhibitors and fracture risk: A review of current evidence and mechanisms involved. Int J Environ Res Public Health 2019; 16(9): 1571. doi: 10.3390/ ijerph16091571.

46. Lee J, Youn K, Choi NK et al. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol 2013; 48(9): 1016–1022. doi: 10.1007/ s00535-012-0722-9.

47. Ruffenach SJ, Siskind MS, Lien YH: Acute interstitial nephritis due to omeprazole. Am J Med 1992; 93(4): 472–473. doi: 10.1016/ 0002-9343(92)90181-a.

48. Blank ML, Parkin L, Paul C et al. A nationwide nested case control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int 2014; 86(4): 837–844. doi: 10.1038/ ki.2014.74.

49. Antoniou T, Macdonald EM, Hollands S et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open 2015;  3(2): E166–E171. doi: 10.9778/ cmajo.20140074.

50. Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case-control study. BMC Nephrol 2013; 16(14): 150. doi: 10.1186/ 1471-2369-14-150.

51. Hart E, Dunn T E, Feuerstein S et al. Proton pump inhibitors and risk of acute and chronic kidney disease: a retrospective cohort study. Pharmacotherapy 2019; 39(4): 443–453. doi: 10.1002/ phar.2235.

52. De Francisco AL, Varas J, Ramos R et al. Proton pump inhibitor usage and the risk of mortality in hemodialysis patients. Kidney Int Rep 2017;  3(2): 374–384. doi: 10.1016/ j.ekir.2017.11.001.

53. Xie Y, Bowe B, Li T et al. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol 2016; 27(10): 3153–3163. doi: 10.1681/ ASN.2015121377.

54. Lazarus B, Chen Y, Wilson FP et al: Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 2016; 176(2): 238–246. doi: 10.1001/ jamainternmed.2015.7193.

55. Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail 2015; 37(7): 1237–1241. doi: 10.3109/ 0886022X.2015.1057800.

56. Toth-Manikowski SM, Grams ME. Proton pump inhibitors and kidney disease – GI upset for the nephrologist? Kidney Int Rep 2017; 2(3): 297–301. doi: 10.1016/ j.ekir.2017.01.005.

57. Keihani S, Craig JR, Zhang C et al. Proton-pump inhibitor use does not affect semen quality in subfertile men. Asian J Androl  2018, 20(3): 290–293. doi: 10.4103/ aja.aja_35_17.

58. Shaikh IA, Masood N, Shaikh TZ. Do proton pump inhibitors harm to semen? Hyderabad Sindh based study. Int J Sex Reprod Health Care 2019; 2(1): 001–009.

59. Novotny M, Klimova B, Valis M. PPI long term use: risk of neurological adverse events? Front. Neurol 2019; 9: 1142. doi: 10.3389/ fneur.2018.01142.

60. Khan MA, Yuan Y, Iqbal U et al. No association linking short-term proton pump inhibitor use to dementia: Systematic review and meta-analysis of observational studies. Am J Gastroenterol 2020; 115(5): 671–678. doi: 10.14309/ ajg.0000000000000500.

61. Wicinski M, Malinowski B, Puk O et al. Possible effects of proton pump inhibitors on hearing loss development.  Biomed Res Int 2019; 4853695. doi: 10.1155/ 2019/ 4853695.

62. Lin BM, Curhan SG, Wang M et al. Prospective study of gastroesophageal reflux, use of proton pump inhibitors and H2-receptor antagonists, and risk of hearing loss. Ear Hear 2017; 38(1): 21–27. doi: 10.1097/ AUD.0000000000000347.

63. Tantai XX, Yang LB, Wei ZC et al. Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: A meta-analysis. World J Gastroenterol 2019; 25(21): 2683–2698. doi: 10.3748/ wjg.v25.i21.2683.

64. De Roza MA, Kai L, Kam JW et al. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol 2019; 25(33): 4933–4944. doi: 10.3748/ wjg.v25.i33.4933.

65. Juurlink DN, Dormuth CR, Huang A et al. Proton pump inhibitors and the risk of adverse cardiac events. PLoS ONE 2013; 8(12): e84890. doi: 10.1371/ journal.pone.0084890.

66. Charlot M, Ahlehoff O, Norgard ML et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use. Ann Int Med 2010; 153(6): 378–386.

67. Shih CJ, Chen YT, Ou SM et al. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int J Cardiol 2014; 177(1): 292–297.

68. Pello Lazaro AM, Cristobal C, Franco-Pelaez JA et al. Use of proton-pump inhibitors predicts heart failure and death in patients with coronary artery disease. PLoS ONE 2017; 12(1): e0169826. doi: 10.1371/ journal. pone.0169826.

69. Fortuna LA, Pawloski PA, Parker ED et al. Proton pump inhibitor use by aspirin-treated coronary artery disease patients is not associated with increased risk of cardiovascular events, Eur Heart J Cardiovasc Pharmacother 2016; 2(1):13–19. doi: 10.1093/ ehjcvp/ pvv036.

70. Shah NH, LePendu P, Bauer-Mehren A et al.Proton pump inhibitor usage and the risk of myocardial infarction in the general population, PLoS ONE 2015; 10(6): e0124653. doi: 10.1371/ journal.pone.0124653.

71. Landi SN, Sandler RS, Pate V et al. No increase in risk of acute myocardial infarction in privately insured adults prescribed proton pump inhibitors vs histamine-2 receptor antago­nists (2002–2014). Gastroenterology 2018; 154(4): 861–873. doi: 10.1053/ j.gastro.2017.10.042.

72. Xie Y, Bowe B, Yan Y et al. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ 2019; 365: l1580. doi: 10.1136/ bmj.l1580.

73. Lambert AA, Lam JO, Paik JJ et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: A systematic review and meta-analysis. PLoS ONE 2015; 10(6): e0128004.doi: 10.1371/ journal.pone.0128004.

74. Dublin S, Walker RL, Jackson ML et al. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study. Pharmacoepidemiol Drug Saf 2010; 19(8): 792–802. doi: 10.1002/ pds.1978.

75. Wang YT, Tsai MC, Wang YH et al. Association between proton pump inhibitors and asthma: a population-based cohort study. Front. Pharmacol 2020; 11: 607. doi: 10.3389/ fphar.2020.00607

76. Lima JJ, Lang JE, Mougey EB et al. Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children. J Pediatr 2013; 163(3): 686–691. doi: 10.1016/ j.jpeds.2013.03.017.

77. Ivashkin V, Zolnikova O, Potskherashvili N et al.Metabolic activity of intestinal microflora in patients with bronchial asthma. Clin Pract 2019; 9(11): 1126. doi: 10.4081/ cp.2019.1126.

78. Robinson LB, Camargo CA Jr. Acid sup­pressant medications and the risk of allergic diseases. Expert Rev Clin Immunol 2018; 14(9): 771–780. doi: 10.1080/ 1744666X.2018.1512405.

79. Devine RE, Sheikh A, Nwaru BI. Acid-suppressive medications during pregnancy and risk of asthma and allergy in the offspring: protocol for a systematic review. NPJ Prim Care Respir Med 2016; 26: 16001. doi: 10.1038/ npjpcrm.2016.1.

80. Aggarwal N. Drug-induced subacute cutaneous lupus erythematosus associated with proton pump inhibitors. Drugs Real World Outcomes 2016; 3(2): 145–154. doi: 10.1007/ s40801-016-0067-4.

81. Brisebois S, Merati A, Giliberto JP. Proton pump inhibitors: Review of reported risks and controversies. Laryngoscope Investig Otolaryngol 2018; 3(6): 457–462. doi: 10.1002/ lio2.187.

82. Sibal L, Sharad C, Agarwal SC et al. The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Curr Cardiol Rev 2010; 6(2): 82–90. doi: 10.2174/ 157340310791162659.